News

Active Filters

S1616 results at AACR 2022
Apr 8, 2022
Reversing resistance to PD-1 inhibitors with combination immunotherapy in patients with advanced melanoma
S1314 at GU ASCO
Feb 15, 2022
Survival data from the first prospective, randomized biomarker validation trial in muscle-invasive bladder cancer presented at GU ASCO
Sex differences in risk of SAEs
Feb 14, 2022
Higher toxicity risk for women was known for chemotherapy, now also identified for immunotherapy and targeted therapy
Results of S1417CD
Jan 4, 2022
Major financial hardship common after cancer diagnosis, despite insurance
Anjali Advani, MD
Dec 13, 2021
Combo with immunotherapy drug can be effective in patients who are not good candidates for chemo
Megan Othus, PhD
Dec 11, 2021
Analyses presented at ASH 2021 find statistical models can predict risk of early death with non-intensive AML therapy
Corey W. Speers, MD, PhD
Dec 9, 2021
Results at SABCS show assay has prognostic value that complements value of recurrence score in postmenopausal patients
RxPONDER Trial Results: Kevin Kalinsky, MD
Dec 1, 2021
RxPONDER finds postmenopausal women with HR+, HER2- breast cancer with 1-3 involved nodes and an RS of 25 or less can safely skip chemo